Valuation: Valneva SE

Market Cap 413M 472M 381M 352M 668M 45.06B 679M 4.55B 1.79B 22.2B 1.77B 1.74B 76.31B P/E 2026 *
-5.94x
P/E 2027 * 5.73x
Enterprise Value 541M 619M 499M 461M 875M 59.02B 890M 5.97B 2.34B 29.07B 2.32B 2.27B 99.95B EV / Sales 2026 *
3.57x
EV / Sales 2027 * 1.61x
Free-Float
97.36%
Yield 2026 *
-
Yield 2027 * -
1 day-4.72%
1 week-6.76%
Current month-3.37%
1 month-2.98%
3 months-18.54%
6 months-48.80%
Current year-41.39%
1 week 2.18
Extreme 2.179
2.36
1 month 2.16
Extreme 2.156
2.37
Current year 2.14
Extreme 2.135
5.15
1 year 2.14
Extreme 2.135
5.42
3 years 1.73
Extreme 1.726
7.24
5 years 1.73
Extreme 1.726
29.7
10 years 1.73
Extreme 1.726
29.7
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 29/07/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 20/12/2023
Director/Board Member 75 07/03/2013
Chairman 65 20/12/2023
Date Insider Type Main position Quantity % Market Cap.
01-27Sell

Chief Technology Officer

11,800 0.0069%
01-26Sell

Chief Financial Officer

11,800 0.0069%
01-19Sell

Chief Operating Officer

6,206 0.0036%
Change 5-day change 1-year change 3-year change Capi.($)
-4.72%-6.76%-14.55%-66.48% 472M
+0.58%+2.06%+2.92%+10.86% 50.73B
-2.22%-1.25%+385.40%+586.81% 39.73B
-0.54%+0.39%+25.57%-5.28% 34.69B
-1.36%+0.35%+17.88%+55.14% 33.21B
+1.21%-4.58%+3.00%+35.46% 26.76B
-1.81%-1.48% - - 16.8B
+0.51%-3.47%+63.97%+122.60% 15.37B
+0.23%-0.58%+13.76%+21.11% 13.78B
-0.62%-3.09%+10.29%-31.35% 12.85B
Average -0.87%-1.42%+56.47%+80.99% 24.44B
Weighted average by Cap. -0.49%-0.24%+80.49%+123.92%

Financials

2026 *2027 *
Net sales 152M 174M 140M 129M 245M 16.55B 250M 1.67B 657M 8.15B 652M 638M 28.04B 294M 336M 271M 250M 475M 32.06B 483M 3.24B 1.27B 15.79B 1.26B 1.23B 54.3B
Net income -66.01M -75.47M -60.89M -56.24M -107M -7.2B -109M -728M -286M -3.55B -283M -277M -12.19B 70.5M 80.6M 65.03M 60.06M 114M 7.69B 116M 777M 305M 3.79B 303M 296M 13.02B
Net Debt 128M 146M 118M 109M 207M 13.96B 210M 1.41B 554M 6.88B 550M 538M 23.64B 60.02M 68.61M 55.36M 51.13M 97.02M 6.54B 98.65M 661M 260M 3.22B 258M 252M 11.08B
Logo Valneva SE
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
674
Date Price Change Volume
10/07/26 €2.179 -4.72% 603,158
09/07/26 €2.287 +0.18% 144,492
08/07/26 €2.283 -0.09% 340,101
07/07/26 €2.285 -1.08% 498,958
06/07/26 €2.310 -1.16% 390,753
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.179EUR
Average target price
5.233EUR
Spread / Average Target
+140.17%

Quarterly revenue - Rate of surprise